Barclays PLC Design Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 96,635 shares of DSGN stock, worth $613,632. This represents 0.0% of its overall portfolio holdings.

Number of Shares

96,635

Previous 96,635 -0.0%

Holding current value

$613,632

Previous $520,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$3.19 - $5.88 $78,480 - $144,659	24,602 Added 34.15%	96,635 $520,000
Q2 2024 Aug 14, 2024	SELL	$3.23 - $4.77 $54,506 - $80,493	-16,875 Reduced 18.98%	72,033 $243,000
Q1 2024 May 15, 2024	SELL	$2.27 - $4.03 $50,044 - $88,845	-22,046 Reduced 19.87%	88,908 $358,000
Q4 2023 Feb 15, 2024	BUY	$1.99 - $2.76 $78,159 - $108,401	39,276 Added 54.8%	110,954 $294,000
Q3 2023 Nov 07, 2023	BUY	$2.05 - $8.14 $114,508 - $454,684	55,858 Added 353.08%	71,678 $170,000
Q2 2023 Aug 03, 2023	SELL	$4.99 - $7.64 $6,971 - $10,673	-1,397 Reduced 8.11%	15,820 $99,000
Q1 2023 May 04, 2023	SELL	$5.5 - $9.77 $625,801 - $1.11 Million	-113,782 Reduced 86.86%	17,217 $99,000
Q4 2022 Feb 13, 2023	BUY	$7.86 - $17.2 $859,891 - $1.88 Million	109,401 Added 506.53%	130,999 $1.34 Million
Q3 2022 Nov 03, 2022	SELL	$14.09 - $25.57 $2.59 Million - $4.7 Million	-183,967 Reduced 89.49%	21,598 $361,000
Q2 2022 Aug 12, 2022	SELL	$9.91 - $17.33 $207,574 - $362,994	-20,946 Reduced 9.25%	205,565 $2.88 Million
Q1 2022 May 16, 2022	BUY	$11.17 - $20.89 $2.53 Million - $4.73 Million	226,511 New	226,511 $3.66 Million

Others Institutions Holding DSGN

# of Institutions

102

Shares Held

31M

Call Options Held

2.3K

Put Options Held

16.5K

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $354M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account